An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 10, 2016, Pages 1730-1741

  Luger, T ^a   Schopf, R E ^b   Schwanke, A ^c   Langhammer, S ^c   Meng, T ^c   Loschmann P A ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BODY SURFACE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DETERIORATION; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROQOL 5 DIMENSION; FEMALE; HUMAN; INFECTION; INFESTATION; INJECTION SITE ERYTHEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEOPLASM; OBSERVATIONAL STUDY; OPEN STUDY; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; MIDDLE AGED; PSORIASIS;

ADULT; ETANERCEPT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS;

EID: 84977139345     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13673     Document Type: Article

References (20)

1. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627–1632.
2. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–2022.
3. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304–1312.
4. Sterry W, Ortonne JP, Kirkham B et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010; 340: c147.
5. van de Kerkhof PC, Segaert S, Lahfa M et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008; 159: 1177–1185.
6. Ortonne JP, Taïeb A, Ormerod AD et al. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol 2009; 161: 1190–1195.
7. Gordon KB, Gottlieb AB, Leonardi CL et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006; 17: 9–17.
8. Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol 2013; 31: S63–S70.
9. Strohal R, Chimenti S, Vena GA, Girolomoni G. Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. J Dermatolog Treat 2013; 24: 199–208.
10. Summary of Product Characteristics. Enbrel 25 mg powder and solvent for solution for injection. 2010. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf (last accessed 3 March 2015).
11. Kimball AB, Rothman KJ, Kricorian G et al. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J Am Acad Dermatol 2015; 72: 115–122.
12. Griffiths CE, Luger TA, Brault Y, Germain JM, Mallbris L. Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study. J Eur Acad Dermatol Venereol 2015; 29: 468–473.
13. Barrera MV, Habicheyn S, Mendiola MV. Herrera Ceballos E. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol 2008; 18: 683–687.
14. Puig L, Camacho Martinez FM, Gimeno Carpio E, López-Ávila A, García-Calvo C. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up. Dermatology 2012; 225: 220–230.
15. Puig L, Camacho F, Garcia-Patos V, Fernandez-Diaz ML, Marquina A, Garcia-Calvo C. Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain, Eur J Dermatol, 2015; 25: 410–417.
16. Daudén E, Griffiths CE, Ortonne JP et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23: 1374–1382.
17. Esposito M, Giunta A, Mazzotta A et al. Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience. Int J Immunopathol Pharmacol 2010; 23: 503–509.
18. Esposito M, Gisondi P, Cassano N et al. Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis.Drug Dev Res 2014;75:S31–S34.
19. Esposito M, Gisondi P, Cassano N et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 2013; 169: 666–672.
20. Segaert S, Ghislain PD, Boone C. An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium). J Dermatolog Treat 2016; 27: 103–109.